Cassava Sciences facing widening probe over short seller claims

Cassava Sciences

The SEC has reportedly launched an investigation into Cassava Sciences regarding allegations made against the clinical-stage biopharmaceutical company and its experimental Alzheimer’s drug by a law firm representing anonymous short sellers.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.